Bone mineral density in long-term survivors of highly malignant osteosarcoma

Journal of Bone and Joint Surgery - Series B

Volumn 85, Issue 2, 2003, Pages 231-237

  Holzer, G ^a   Krepler, P ^a   Koschat, M A ^b   Grampp, S ^a   Dominkus, M ^a   Kotz, R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCITONIN; CALCIUM; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ESTROGEN; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; OSTEOCALCIN; PARATHYROID HORMONE; VINCRISTINE; VITAMIN D;

ADULT; AGE; ANAMNESIS; ARTICLE; AUSTRALIA; BONE DENSITY; BONE MINERAL; BONE RESECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FEMUR; FOLLOW UP; GERMANY; HUMAN; LIFESTYLE; LIMB AMPUTATION; LIMB FRACTURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NETHERLANDS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSARCOMA; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; OSTEOSARCOMA;

EID: 0037357135     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.85B2.13257     Document Type: Article

References (32)

1. Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvant therapy for localised osteosarcoma of extremities: results from the Cooperative Osteosarcoma Study Group. Klin Pädiatr 1999;211:260-70.
2. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 2000;35:415-20.
3. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-63.
4. Slosman DO, Rizzoli R, Pichard C, Donath A, Bonjour JP. Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int 1994;4:185-90.
5. Stanisavljevic S, Babcock A. Fractures in children treated with methotrexate for leukemia. Clin Orthop 1977;125:139-44.
6. Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970;25:580-5.
7. May KP, Mercill D, McDermott MT, West SG. The effect of methotrexate on mouse bone cells in culture. Arthritis Rheum 1996;39:489-94.
8. Zonneveld IM, Bakker WK, Dijkstra PF, et al. Methotrexate osteopathy in long term low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996;132:184-7.
9. Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol 1996;18:367-71.
10. Arikoski P, Komulainen J, Riikonen P, et al. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 1999;14:2002-9.
11. Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G. The effects of methotrexate (MTX) on bone: a densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol 1988;14:227-31.
12. Ripamonti C, Avella M, Gnudi S, Figus E. Effect of high and low doses of methotrexate (MTX) on bone mass in subjects treated for osteosarcoma of the limbs. Minerva Med 1993;84:131-4.
13. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumours of the musculoskeletal system. Clin Orthop 1993;286:241-6.
14. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980;153:106-20.
15. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe 1983;4:135-41.
16. Genant HK, Grampp S, Glüer CC, et al. Universal standardization for dual X-ray absorptiometry: patients and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14.
17. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. Osteoporos Int 1996;6:256-61.
18. Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996;11:707-30.
19. Grampp S, Jergas M, Gluer CC, et al. Radiologic diagnosis of osteoporosis: current methods and perspectives. Radiol Clin North Am 1993;31:1133-45.
20. Bickel PJ, Doksum. Mathematical statistics. Vol. 1. 2nd edition. Upper Saddle River, New Jersey: Prentice Hall, 2001.
21. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
22. Decker S, Winkelmann W, Nies B, van Valen F. Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro. J Bone Joint Surg [Br] 1999;81-B:545-51.
23. Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy. J Rheumatol 2001;28:251-6.
24. Wheeler DL, Vander-Griend RA, Wronski TJ, et al. The short- and long-term effects of methotrexate on the rat skeleton. Bone 1995;16:215-21.
25. Buckley L, Leib E, Cartularo K, Vacek PM, Cooper S. Effects of low-dose methotrexate (MTX) treatment on bone mineral density (BMD) in patients with rheumatoid arthritis. Arthritis Rheum 38 (Suppl): S312.
26. West SG, Hugler R, Battafarano D, McDermott MT, McBiles. Low-dose weekly methotrexate (MTX) does not cause osteoporosis rheumatoid arthritis (RA) patients. Arthritis Rheum 38 (Suppl):S312.
27. Bianchi ML, Cimaz R, Galbiati E, et al. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporosis Int 1999;10:20-5.
28. Carbone LD, Kaeley G, McKown KM, et al. Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. Calcif Tissue Int 1999;64:100-1.
29. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993;8:567-73.
30. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine 1997;22(24 Suppl):17-24.
31. Anai T, Miyazaki F, Tomiyasu T, Matsuo T. Risk of irregular menstrual cycles and low peak bone mass during early adulthood associated with age at menarche. Pediatr Int 2001;43:483-8.
32. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med 2000;45:241-7.